27Nov/080
TENNCARE OFFICIALS ASK COURT TO SUSPEND LAWSUIT THAT PREVENTS RE-EVALUATION OF SOME BENEFICIARIES’ ELIGIBILITY
TennCare officials have asked that courts grant them a suspension of a 20-year-old lawsuit that prevents the state from annually re-evaluating about 180,000 beneficiaries who may no longer be eligible for coverage, the AP/Tennessean reports. TennCare is the state's expanded Medicaid program.Gov.27Nov/080
NON-ATTENDANCE AT THE COLORECTAL CLINIC: A PROSPECTIVE AUDIT
docserver.ingentaconnect.com
27Nov/080
NON-COMPLIANCE WITH APPOINTMENTS AMONGST
external.doyma.es
27Nov/080
THE EFFECT OF TELEPHONE REMINDERS ON ATTENDANCE IN RESPIRATORY OUTPATIENT CLINICS.
Journal of health services research & policy 12 (2), 69-72 (Apr 2007)
27Nov/080
“DON’T ILLEGALLY PROMOTE MEDICINES” ADVISES MEDICINE REGULATOR
The Medicines and Healthcare products Regulatory Agency (MHRA) is publishing advice for consumer websites about the rules governing the advertising of medicines. The MHRA wants to help companies to work within the parameters of the Medicines Advertising Regulations. The guidance covers all websites registered in the UK or aimed at UK consumers which provide services that may lead to the prescription and or the supply of a prescription only medicine (POM).27Nov/080
TEVA ANNOUNCES AGREEMENT ON GENERIC PULMICORT RESPULES(R) PATENT CHALLENGE
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva's U.S. generic version of AstraZeneca's Pulmicort (Budesonide) Respules® including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The agreement releases Teva for all past U.S.27Nov/080
CIMETIDINE ENHANCES IMMUNE RESPONSE OF HBV DNA VACCINATION VIA IMPAIRMENT OF THE REGULATORY FUNCTION OF REGULATORY T CELLS
Biochemical and Biophysical Research Communications, Vol. 372, No. 3. (01 August 2008), pp. 491-496.Cimetidine (CIM), a histamine 2-receptor antagonist, is postulated to enhance immune responses owing to its inhibitory effects on suppressor T cells. In this report, we evaluated effects of cimetidine on the potency of antigen-specific immunity generated by DNA vaccine encoding hepatitis B surface antigen (HBsAg, pcD-S2). Our data demonstrate that CIM as adjuvant significantly increased HBsAg-specific cell-mediated and humoral immunities that were characterized by higher Ig2a/IgG1 ratio. In addition, CIM significantly promotes an elevated level of IL-4 and IFN-? in antigen-specific CD4+ T cells and a robust antigen-specific cytotoxic response in the animals immunized with pcD-S2 plus CIM. Further, CIM induces pro-inflammatory cytokine expression such as the IL-12 and down-regulates anti-inflammatory cytokine expression such as IL-10 and TGF-?, which may lead to an impairment of CD4+CD25+ Treg cell-mediated suppression. Collectively these findings suggest that CIM enhances the immune responses of HBV DNA vaccine through the stimulation of pro-inflammatory and inhibition of anti-inflammatory cytokine expression patterns.
J Wang, B Su, Z Ding, X Du, B Wang
27Nov/080
NATURE EDUCATION’S SCITABLE: FOR SCIENCE STUDENTS EVERYWHERE
Nature Education recently launched the beta for Scitable (pronounced sight-?-b?l, as in a “citable source”). Described as “a collaborative learning space for science undergraduates,” the project’s goal is two-fold: to foster and cultivate students’ interest in science, and to provide an accessible source of current scientific knowledge to science students worldwide. (Image courtesy of Nature Publishing [...]26Nov/080
